利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.024 秒)

    DRUG CARTRIDGE FOR DELIVERING A DRUG DEPOT COMPRISING A BULKING AGENT AND/OR COVER
    1.
    发明申请
    DRUG CARTRIDGE FOR DELIVERING A DRUG DEPOT COMPRISING A BULKING AGENT AND/OR COVER 有权
    用于递送含有破坏剂和/或覆盖物的药物盒的药物盒

    公开(公告)号：US20100106133A1

    公开(公告)日：2010-04-29

    申请号：US12260876

    申请日：2008-10-29

    申请人： Thomas A. Simonton ,  John M. Zanella ,  Vanja King

    发明人： Thomas A. Simonton ,  John M. Zanella ,  Vanja King

    IPC分类号： A61M5/31

    CPC分类号： A61M37/0069 ,  A61M31/007

    摘要： A drug cartridge is provided for delivering a drug pellet to a site beneath the skin of a patient, the drug cartridge comprising: two or more chambers, each chamber holding a drug pellet and having a proximal end and a distal end, the proximal end of the chamber having an opening to receive the drug pellet and a plunger, the distal end of the chamber having an opening for receiving the plunger and passage of the drug pellet, a bulking agent disposed within at least a portion of each chamber, wherein movement of the plunger to an extended position moves the drug pellet within the chamber of the cartridge out the distal end of the chamber and out of the drug cartridge. In some embodiments, instead or with the bulking agent pierceable superior and inferior covers are used to contain the drug pellets.

    摘要翻译： 提供了药物盒，用于将药物丸粒输送到患者皮肤下方的部位，药物盒包括：两个或更多个腔室，每个腔室容纳药物丸粒并具有近端和远端，近端 所述腔室具有用于接收药物丸粒的开口和柱塞，所述腔室的远端具有用于接收柱塞和药物丸粒通道的开口，设置在每个腔室的至少一部分内的填充剂，其中， 柱塞到延伸位置将药筒内的药丸从药筒的远端移出药物盒。 在一些实施方案中，替代地或与填充剂可刺穿的上下盖用于容纳药物颗粒。

    Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
    2.
    发明授权
    Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover 有权
    用于递送包含填充剂和/或盖的药物贮库的药筒

    公开(公告)号：US09352137B2

    公开(公告)日：2016-05-31

    申请号：US12260876

    申请日：2008-10-29

    申请人： Thomas A. Simonton ,  John M. Zanella ,  Vanja King

    发明人： Thomas A. Simonton ,  John M. Zanella ,  Vanja King

    IPC分类号： A61M37/00 ,  A61M31/00

    CPC分类号： A61M37/0069 ,  A61M31/007

    摘要： A drug cartridge is provided for delivering a drug pellet to a site beneath the skin of a patient, the drug cartridge comprising: two or more chambers, each chamber holding a drug pellet and having a proximal end and a distal end, the proximal end of the chamber having an opening to receive the drug pellet and a plunger, the distal end of the chamber having an opening for receiving the plunger and passage of the drug pellet, a bulking agent disposed within at least a portion of each chamber, wherein movement of the plunger to an extended position moves the drug pellet within the chamber of the cartridge out the distal end of the chamber and out of the drug cartridge. In some embodiments, instead or with the bulking agent pierceable superior and inferior covers are used to contain the drug pellets.

    摘要翻译： 提供了药物盒，用于将药物丸粒输送到患者皮肤下方的部位，药物盒包括：两个或更多个腔室，每个腔室容纳药物丸粒并具有近端和远端，近端 所述腔室具有用于接收药物丸粒的开口和柱塞，所述腔室的远端具有用于接收柱塞和药物丸粒通道的开口，设置在每个腔室的至少一部分内的填充剂，其中， 柱塞到延伸位置将药筒内的药丸从药筒的远端移出药物盒。 在一些实施方案中，替代地或与填充剂可刺穿的上下盖用于容纳药物颗粒。

    Modification of chemical forces of bone constructs
    3.
    发明授权
    Modification of chemical forces of bone constructs 有权
    骨构建体化学力的修改

    公开(公告)号：US07749555B2

    公开(公告)日：2010-07-06

    申请号：US11339781

    申请日：2006-01-25

    申请人： John M. Zanella ,  Sean M. Haddock ,  Catherine E. Taylor ,  Kathryn J. Kitching

    发明人： John M. Zanella ,  Sean M. Haddock ,  Catherine E. Taylor ,  Kathryn J. Kitching

    IPC分类号： B05D3/04 ,  A61F2/28

    CPC分类号： A61L27/50 ,  A61F2/4644 ,  A61F2/468 ,  A61F2002/2817 ,  A61F2002/2821 ,  A61F2002/2835 ,  A61L2430/02 ,  Y10S623/919

    摘要： The present invention relates to a method for enhancing ingrowth of host bone comprising: modifying a bone graft structure to provide an ionic gradient to produce a modified bone graft structure; and implanting the modified bone graft structure. The present invention also relates to a method of enhancing the binding of growth factors and cell cultures to a bone graft structure comprising: applying ex vivo an effective quantity of an ionic force change agent to the surface of a bone graft structure to produce a binding-sensitized bone graft structure; implanting the binding-sensitized bone graft structure into a host bone; and administering to the binding-sensitized bone graft structure a molecule, a cell culture or a combination thereof.

    摘要翻译： 本发明涉及一种用于增强宿主骨向内生长的方法，包括：修饰骨移植结构以提供离子梯度以产生修饰的骨移植结构; 并植入修饰的骨移植结构。 本发明还涉及增强生长因子和细胞培养物与骨移植结构的结合的方法，其包括：将有效量的离子力变化剂离体施加到骨移植结构的表面以产生结合 - 敏化骨移植结构; 将结合敏化的骨移植结构植入宿主骨中; 以及向结合敏化的骨移植结构施用分子，细胞培养物或其组合。

    Surface treatments of an allograft to improve binding of growth factors and cells
    4.
    发明申请
    Surface treatments of an allograft to improve binding of growth factors and cells 审中-公开
    同种异体移植物的表面处理以改善生长因子和细胞的结合

    公开(公告)号：US20080114465A1

    公开(公告)日：2008-05-15

    申请号：US11598900

    申请日：2006-11-14

    申请人： John M. Zanella ,  William F. McKay

    发明人： John M. Zanella ,  William F. McKay

    IPC分类号： A61F2/28

    CPC分类号： A61L27/365 ,  A61L27/3608 ,  A61L27/3847 ,  A61L27/40

    摘要： A method for enhancing the binding of growth factors and/or cells to an allograft structure by applying an effective quantity of a coating material to the surface of the allograft structure, producing a thin coated allograft structure, administering to the thin coated allograft structure a growth factor, cells or a combination thereof, and implanting the thin coated allograft structure into a host bone.

    摘要翻译： 一种通过将有效量的涂层材料施用于同种异体移植物结构的表面来增强生长因子和/或细胞与同种异体移植物结构的结合的方法，产生薄涂层的同种异体移植结构，向薄涂层的同种异体移植结构施用生长 因子，细胞或其组合，以及将薄涂层的同种异体移植物结构植入宿主骨中。

    Methods of treating tendonitis in a subject by using an anti-cytokine agent
    6.
    发明申请
    Methods of treating tendonitis in a subject by using an anti-cytokine agent 审中-公开
    通过使用抗细胞因子剂治疗受试者的腱炎的方法

    公开(公告)号：US20080064626A1

    公开(公告)日：2008-03-13

    申请号：US11517772

    申请日：2006-09-08

    申请人： John M. Zanella

    发明人： John M. Zanella

    IPC分类号： A61K38/17

    CPC分类号： C07K16/24 ,  A61K2039/505

    摘要： A method for treating tendonitis and bursitis in a subject involves providing an effective amount of an anti-cytokine agent to a musculo-tendinious structure. Anti-cytokine agents, such as, TNF-α inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors, IL-10, Interferon-gamma (IFN-gamma) act to prevent further inflammation initiated by cytokine factors. One embodiment includes, adding with the anti-cytokine agent one or more of an antibiotic or analgesic. Delivery of the anti-cytokine agent may be provided to the affected musculo-tendinious structure by injection, implantation, or a transdermal patch. These agents, individually or in combination directly address the underlying causes of tendonitis, bursitis and associated tendinopathies that result in inflammation and pain.

    摘要翻译： 用于治疗受试者的腱炎和滑囊炎的方法涉及向肌肉倾向结构提供有效量的抗细胞因子试剂。 抗细胞因子剂如TNF-α抑制剂，NF-κB抑制剂，IL-1抑制剂，IL-6抑制剂，IL-8抑制剂，IL-12抑制剂，IL-15抑制剂，IL-10，干扰素-γ （IFN-γ）用于预防由细胞因子因子引起的进一步炎症。 一个实施方案包括用抗细胞因子剂加入抗生素或止痛剂中的一种或多种。 可以通过注射，植入或经皮贴片向受影响的肌肉结构结构提供抗细胞因子剂的递送。 这些药物单独或组合直接解决导致炎症和疼痛的腱炎，滑囊炎和相关性肌腱炎的根本原因。

    SULINDAC FORMULATIONS IN A BIODEGRADABLE MATERIAL
    9.
    发明申请
    SULINDAC FORMULATIONS IN A BIODEGRADABLE MATERIAL 有权
    生物可降解材料中的SULINDAC配方

    公开(公告)号：US20090264531A1

    公开(公告)日：2009-10-22

    申请号：US12413236

    申请日：2009-03-27

    申请人： John M. Zanella ,  Vanja M. King ,  Christopher M. Hobot ,  S. Mark Cox ,  Danielle Biggs ,  Katara Shaw ,  William F. McKay ,  Kathy L. Remsen

    发明人： John M. Zanella ,  Vanja M. King ,  Christopher M. Hobot ,  S. Mark Cox ,  Danielle Biggs ,  Katara Shaw ,  William F. McKay ,  Kathy L. Remsen

    IPC分类号： A61K31/192 ,  A61P25/00 ,  A61P29/00

    CPC分类号： A61K31/255 ,  A61K9/0024 ,  A61K9/204

    摘要： Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

    摘要翻译： 提供了长时间疼痛和/或炎症的有效治疗。 通过在目标部位处或附近施用有效量的舒林酸或其药学上可接受的盐，可以减轻由不同来源引起的疼痛和/或炎症，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊椎脱位， 狭窄，恶性背痛和关节疼痛以及手术附带的疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天，至少二十五天。 在一些实施例中，浮雕可以是至少五十天，至少一百天，至少一百三十五天或至少一百八十天。

    Use Of Anti-Cytokine Agents For Treating Carpal And Tarsal Tunnel Syndrome
    10.
    发明申请
    Use Of Anti-Cytokine Agents For Treating Carpal And Tarsal Tunnel Syndrome 有权
    使用抗细胞因子剂治疗腕管和T骨隧道综合征

    公开(公告)号：US20080124383A1

    公开(公告)日：2008-05-29

    申请号：US11563920

    申请日：2006-11-28

    申请人： John M. Zanella

    发明人： John M. Zanella

    IPC分类号： A61M5/142 ,  A61M1/00 ,  A61K9/70 ,  A61P43/00 ,  A61M25/00

    CPC分类号： A61K38/1793 ,  A61K9/0019 ,  A61K9/7023

    摘要： Methods for treating carpal tunnel syndrome and tarsal tunnel syndrome in a subject involve providing an effective amount of an anti-cytokine agent at or near inflammation in the carpal or tarsal tunnel. Anti-cytokine agents, such as, TNF-a inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors, IL-10, Interferon-gamma (IFN-?) act to prevent further inflammation initiated by cytokine factors. One embodiment includes, adding with the anti-cytokine agent one or more of an antibiotic or analgesic. Delivery of the anti-cytokine agent may be provided to the inflamed tissue of the carpal or tarsal tunnel by injection, implantation, or a transdermal patch. These agents, individually or in combination, directly address the underlying inflammation that causes the discomfort, pain, and restricted movement associated with carpal and tarsal tunnel syndrome.

    摘要翻译： 在受试者中治疗腕管综合征和t疮综合征的方法涉及在腕管或t al洞中或炎症附近提供有效量的抗细胞因子剂。 抗细胞因子剂如TNF-α抑制剂，NF-κB抑制剂，IL-1抑制剂，IL-6抑制剂，IL-8抑制剂，IL-12抑制剂，IL-15抑制剂，IL-10，干扰素-γ （IFN-α）起到预防由细胞因子因子引起的进一步炎症的作用。 一个实施方案包括用抗细胞因子剂加入抗生素或止痛剂中的一种或多种。 可以通过注射，植入或透皮贴剂将递送的抗细胞因子试剂提供给腕管或t骨隧道的发炎组织。 这些药物单独地或组合地直接解决引起与腕骨和t骨隧道综合征相关的不适，疼痛和受限运动的潜在炎症。